查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837454

血液培养检测市场按产品、最终用户、技术、检测类型、应用、样本类型和模式划分 - 全球预测 2025-2032

Blood Culture Test Market by Product, End User, Technology, Test Type, Application, Sample Type, Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血液培养检测市场规模将达到 73.6 亿美元，复合年增长率为 6.36%。

主要市场统计数据
基准年 2024 44.9亿美元
预计年份：2025年 47.8亿美元
预测年份：2032年 73.6亿美元
复合年增长率 (%) 6.36%

简要说明血液培养诊断在现代医疗保健服务体系中不断演变的临床和运作意义

血液培养检测仍然是诊断血流感染疾病和指导抗菌治疗的基本诊断程序。儘管培养系统、自动化和分子辅助技术的进步提高了血液培养工作流程的临床相关性和操作效率，但实验室在检体处理过程中仍需不断权衡速度、灵敏度和成本。在临床实践中，及时检测能够直接影响患者的预后，因为它能够指导标靶治疗并减少不必要的抗菌药物暴露。

同时，实验室管理人员和采购专业人员必须应对由技术整合、供应链动态和不断变化的监管预期所塑造的全新环境。自动化分析仪与前端检体处理和资料连接的整合提高了检测的一致性并缩短了周转时间，但也引入了新的供应商互通性和验证方面的考虑。随着医疗保健系统将诊断管理和实验室效率置于优先地位，医院系统、独立实验室和门诊机构的血液培养检测正在经历营运改善和策略重新评估。

本执行摘要概述了目前影响临床实践、技术应用和组织投资决策的动态。它重点阐述了诊断范式、政策环境和终端使用者需求的变化如何重塑采购偏好和实施策略，这对临床实验室、设备製造商和医疗保健管理者在寻求优化整个医疗服务过程中的诊断价值时具有重要意义。

技术创新、自动化、供应链韧性和诊断管理如何重塑血液培养检测的实验室工作流程和临床管道

技术创新、工作流程优化以及实验室在诊疗路径中角色的重塑，正在改变血液感染的诊断模式。儘管传统培养技术仍能提供重要的表型讯息，但分子平台和快速鑑定方法已拓展了临床医生的套件，使其能够更早停止经验性治疗并加强抗菌药物管理。这种技术变革时期促使实验室重新评估其检测流程，并采用培养和分子方法互补的混合方法。

在营运方面，分析前和分析阶段自动化程度的不断提高正在改变实验室的人员配置模式和处理量预期。自动化减少了人为操作的差异，并支援更高的样本量，但也需要对培训、验证和资讯学进行投资，以确保无缝整合。同时，供应链韧性已成为一项策略重点。实验室和供应商正在探索耗材采购的冗余方案，并实现物流多元化，以减少中断风险。

在临床方面，受支付方审查和机构品质改进倡议的推动，诊断管理日益受到重视。诊断流程正在重新设计，旨在强调及时准确的检测，同时避免不必要的检查。这种转变正在影响自动化和手动检测方法的应用模式，并凸显了可操作报告、结果週转时间和与临床决策支援系统整合的重要性。总而言之，这些趋势不仅正在重塑实验室运营，也为供应商和医疗系统创造了新的合作机会，共同开发能够带来可衡量的临床和经济价值的整合解决方案。

评估关税主导的采购压力因素和供应链策略对血液培养诊断整体成本结构、采购决策和分销模式的影响

近期关税政策的变化和贸易政策的调整对参与血液培养诊断的临床实验室、製造商和经销商产生了显着的下游影响。某些检测设备和耗材进口关税的提高可能导致到岸成本上升，迫使采购团队重新评估供应商组合，并协商长期合约以稳定价格。为此，製造商正在考虑生产在地化、替代筹资策略以及产品组合调整，以在维持利润率的同时减轻关税的影响。

这些动态将影响终端使用者的采购行为，医院和独立实验室需要在单位成本、供应可靠性和供应商支援承诺之间权衡取舍。有些机构会优先建立关键耗材库存以应对价格波动，而有些机构则会寻求能够降低资本支出并透过管理服务或租赁协议将供应风险转移给供应商的服务模式。此外，成本上升可能会加速各机构对自动化和工作流程效率提升措施的兴趣，因为他们希望透过节省人事费用和减少浪费来抵消不断上涨的单位成本。

同时，关税实施带来的监管和海关方面的复杂性延长了新型分析仪器和耗材的前置作业时间，并使其上市策略更加复杂。因此，开发商和经销商正在调整其分销物流框架，提高整个供应链的透明度，并与客户合作制定紧急时应对计画。总而言之，这些变化正在推动更具策略性的采购规划，鼓励供应商多元化，并奖励企业投资于供应链透明度和在地化生产，以减轻关税相关成本压力的累积影响。

综合細項分析概述了产品、最终用户、技术、测试类型、应用、样本类型和模式对产品采纳和采购动态的影响。

对产品类型的详细分析揭示了影响耗材和实验室设备采购行为的明确因素。耗材，包括试管、培养基和试剂组，是经常性运作成本的主要来源，其评估重点在于批次间一致性、储存需求以及与自动化系统的兼容性。设备，包括分析仪和自动化系统，则需要进行资本规划、与实验室资讯系统整合以及签订长期服务合约。因此，采购决策通常需要在耗材供应的可预测性与分析仪部署所带来的效率提升和检验负担之间取得平衡。

终端使用者细分显示，门诊中心、血库、诊断实验室和医院门诊部各自遵循不同的营运模式和采购需求。门诊中心通常分为独立诊所和医生办公室，其中医生办公室优先考虑易用性和占地面积小。血库优先考虑可靠性和合规性，而诊断实验室（包括医院附属实验室和独立实验室）则优先考虑吞吐量、週转时间和互通性。在医院门诊部领域，二级和三级医院需要可扩展的解决方案，其中三级医院通常会整合先进的识别技术。

传统方法和分子生物学方法之间的技术选择决定了诊断途径。虽然传统培养仍然是药敏试验和表型确认的关键，但诸如新一代定序和聚合酵素链锁反应等分子方法正越来越多地用于复杂病例的快速鑑定和表征。自动化和手动工作流程中的检测类型偏好反映了机构的优先事项。自动化平台有利于提高检测的一致性并缩短週转时间，而手动检测可能在样本量较小或资源有限的环境中继续使用。细菌学检测分为革兰氏阴性菌和革兰氏阳性菌检测，真菌检测涵盖霉菌和酵母，而分枝桿菌检测则需要特殊的处理方法。血浆和全血检体类型会影响处理方案和设备相容性，而集中式和照护现场（包括床边检测和可携式检测）等交付方式则决定了检测能力的分散式和集中式。这些细分视角构成了一个多维框架，可用于客製化产品开发、商业化和临床应用策略。

影响美洲、欧洲、中东和非洲以及亚太地区技术采纳、采购偏好和服务模式的区域动态和基础设施因素

地理动态导緻美洲、欧洲、中东和非洲以及亚太地区的需求驱动因素和营运限制各不相同，这反映了各自不同的医疗基础设施、报销模式和区域供应链架构。在美洲，大型综合医疗系统和对诊断管理的重视影响着人们对高效能自动化和互联互通的偏好。在欧洲、中东和非洲，监管协调工作与不同的采购框架和基础设施异质性并存，这为模组化解决方案提供了机会，以应对不同的临床环境。在亚太地区，快速发展的实验室网络与成熟的卓越中心相结合，推动了人们对可扩展自动化和分子支持设备的浓厚兴趣，以应对地方性感染和医院获得性感染的挑战。

不同地区的筹资策略在平衡资本支出和营运支出方面存在差异。资金雄厚的地区通常需要先进的分析设备和整合自动化系统来支援高通量工作流程，而资源有限的地区则更依赖人工或半自动化方法以及耐用耗材。随着跨境物流和关税制度进一步影响分销策略，供应商和医疗系统必须考虑区域仓库、区域合作伙伴关係和灵活的服务模式，以确保供应的可靠性。值得注意的是，抗菌素抗药性监测、败血症管理计画和公共卫生报告等临床重点会影响特定技术和检测方法的应用。

竞争优势源自于一体化的解决方案组合、强大的服务网络以及与实验室工作流程和临床重点一致的有针对性的创新。

在血液培养检测生态系统中，产品可靠性、整合能力和服务卓越性将决定企业的竞争地位。拥有丰富耗材和仪器产品组合的领导企业，将透过提供端到端解决方案来降低供应商管理的复杂性并检验无缝工作流程，从而获得优势。投资于互通性、数据整合和以使用者为中心的设计，以最大限度地减少人工操作时间并简化结果报告流程的企业，将增强其对高通量实验室和医院系统的价值提案。相反，专注于快速分子鑑定或高灵敏度检测等细分技术领域的专业公司，可以在将先进诊断视为优先事项的参考中心和三级医院中占据战略地位。

伙伴关係策略和通路模式也是区分不同竞争策略的关键因素。那些拥有强大的经销商网路和本地技术支援的公司，能够更好地服务于多元化的地域市场；而那些提供嵌入式服务项目、再贷款方案和按绩效付费合约的公司，则可以缓解客户的资金压力。此外，在供应链中断时期展现出透明度和应对力的公司，能够与机构投资者建立信任和长期合作关係。整合自动化、分子辅助试剂和数位化报告功能的创新产品线能够提升临床和营运效益，而那些将研发投资与实际实验室工作流程结合的企业，更有可能在采购决策中获得优先考虑。

最终，一家公司的成功越来越取决于它能否提供可证明的营运效率、符合监管规定的绩效以及可扩展的支援模式，以符合其多样化实验室客户的临床和财务目标。

为供应商和实验室领导者提供可操作的策略重点，以提升诊断价值、营运韧性和以合作伙伴为中心的商业化模式。

产业领导者若想巩固市场地位并提升临床影响力，应着重投资于提高诊断价值和增强营运韧性这两大目标。首先，应优先考虑能够连接表型培养和快速分子鑑定，并在现有实验室工作流程限制下提供临床可操作结果的解决方案。这样做既能使机构及时为临床医生提供信息，又能满足下游表型药敏试验的需求。其次，应投资于自动化和资讯科学，以减少人为操作差异并缩短週转时间，同时确保技术应用配备完善的培训和检验机制。

第三，我们透过多元化采购、区域仓储和透明的库存管理来建立供应链弹性。这些措施降低了关税引发的成本转移和物流瓶颈带来的风险。第四，我们透过以结果为导向的服务产品与终端用户互动，例如试剂租赁模式、试剂管理项目和绩效保证型契约服务将供应商的激励机制与实验室的吞吐量和品质目标相结合。第五，我们寻求与临床团队的伙伴关係，并将诊断管理原则融入检测演算法和报告格式，以加强检测结果与治疗决策之间的连结。最后，我们在产品设计中融入可扩展性，使我们的解决方案能够适应门诊中心、血库、参考文献实验室和医院系统，并支援与资本週期和临床需求相适应的增量升级和模组化部署。

采用严谨的混合方法研究途径，结合实务工作者访谈、技术文献和检验步骤，以获得实用、可复製的诊断见解。

本研究采用混合方法，综合分析了与血液培养诊断相关的临床、商业性和营运方面的见解。一级资讯来源包括对实验室主任、采购负责人和临床微生物学家的结构化访谈，以深入了解工作流程的限制、验证实践和临床应用案例。二级资讯来源包括同行评审文献、监管指南和製造商技术文檔，以确认其符合现行标准和预期绩效。分析整合了产品类型、最终用户、技术和地区的横断面比较和定性主题综合，以识别一致的模式和差异化驱动因素。

为提高可靠性，研究结果透过多通路资料进行三角验证，并在专家评审会议上根据从业人员的回馈检验。调查方法的保障措施包括：在文献和技术文件中清晰记录纳入标准，并仔细阐明技术定义，以区分传统培养方法和分子辅助方法。此外，还概述了资料来源、访谈通讯协定和分析框架，以确保研究结果的可重复性，并允许相关人员质疑假设，并将研究结果应用于自身的实际操作环境中。这项综合研究在强调实际应用价值的同时，也基于既定的实验室实践和当前的诊断趋势，为策略规划和营运优化提供了可靠的基础。

整合临床、营运和策略要务，指南血液培养诊断解决方案的有效部署和永续发展

血液培养诊断正处于曲折点，技术创新、供应链考量和临床需求正在融合，重塑实验室实践。儘管传统培养系统仍然是表型药敏试验的基础，但分子和自动化辅助技术正在重新定义人们对速度和诊断解析度的期望。这些互补的模式为混合诊断管道创造了机会，兼顾快速鑑定和全面的药敏测定，从而改善血液管理和患者预后。在营运方面，实验室在采用新平台时，必须应对与关税相关的成本压力、供应链波动以及整合和检验的要求。

强调互通性、在地供应链韧性和以结果为导向的服务模式的策略应对措施，最有可能有效维持绩效和价值。针对不同终端使用者（从床边即时检测到高通量标准实验室）的细微需求客製化产品系列，将使供应商和医疗机构能够在控制整体营运成本的同时提高诊断效率。展望未来，连结製造商、实验室负责人和临床团队的协作方式将加速技术进步转化为可衡量的临床效益，为疑似血流感染患者提供更安全、更快速、更有针对性的治疗。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧驱动的病原体鑑定软体整合到自动化血液培养平台中，以实现更快的诊断
  • 扩大快速分子血液培养检测规模，以便在护理点检测抗菌药物抗药性标记物
  • 引进连续监测血液培养系统以缩短加加护病房的检测时间
  • 开发结合传统培养方法的多重PCR检测板，用于全面筛检败血症病原体。
  • 加强诊断公司与医院之间的合作，以实施抗菌药物管理计划
  • 诸如体外诊断医疗器材法规（IVDR）等新的法规结构正在影响欧洲血液培养诊断的设计和检验。
  • 偏远和资源匮乏的医疗机构对可携式床边血液培养设备的需求日益增长
  • 新冠疫情对医院血液培养利用率及败血症管理通讯协定的影响
  • 重点关註一次性血液培养瓶及辅助耗材的永续性和减少塑胶废弃物。
  • 策略性併购推动领先血液培养系统製造商的整合

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 血液培养检测产品市场

  • 消耗品
    • 瓶子
    • 培养基
    • 试剂组
  • 装置
    • 分析器
    • 自动化系统

第九章 依最终用户分類的血液培养检测市场

  • 门诊治疗中心
    • 独立诊所
    • 诊所
  • 血库
  • 诊断实验室
    • 医院实验室
    • 独立实验室
  • 医院和诊所
    • 二级医院
    • 三级医院

第十章 按技术分類的血液培养检测市场

  • 传统的
  • 分子
    • 下一代定序
    • 聚合酵素链锁反应

第十一章 依检测类型分類的血液培养检测市场

  • 自动的
  • 手动的

第十二章 按应用分類的血液培养检测市场

  • 细菌
    • 革兰氏阴性菌
    • 革兰氏阳性菌
  • 真菌
    • 丝状真菌
    • 酵母菌
  • 抗酸桿菌

第十三章 依样本类型分類的血液培养检测市场

  • 电浆
  • 全血

第十四章 血液培养检测市场（依模式划分）

  • 中央实验室
  • 照护现场
    • 床头
    • 可携式的

第十五章 各地区血液培养检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 血液培养检测市场（依集团划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国血液培养检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Becton Dickinson and Company
    • bioMerieux SA
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Accelerate Diagnostics, Inc.
    • bio-Rad Laboratories, Inc.
    • Sigma-Aldrich
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche
Product Code: MRR-035DA3C63737

The Blood Culture Test Market is projected to grow by USD 7.36 billion at a CAGR of 6.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.49 billion
Estimated Year [2025] USD 4.78 billion
Forecast Year [2032] USD 7.36 billion
CAGR (%) 6.36%

A concise orientation to the evolving clinical and operational significance of blood culture diagnostics within modern healthcare delivery systems

Blood culture testing remains a foundational diagnostic procedure for detecting bloodstream infections and guiding antimicrobial therapy. Advances in culture systems, automation, and molecular adjuncts have increased the clinical relevance and operational throughput of blood culture workflows, while laboratories continually balance speed, sensitivity, and cost in specimen processing. In clinical settings, timely detection directly influences patient outcomes by informing targeted therapy and reducing inappropriate antimicrobial exposure, making blood culture capability a critical component of acute care pathways.

In parallel, laboratory managers and procurement specialists must navigate a landscape shaped by technology convergence, supply chain dynamics, and evolving regulatory expectations. The integration of automated analyzers with front-end specimen handling and data connectivity has improved consistency and reduced hands-on time, yet it has also introduced new vendor interoperability and validation considerations. As healthcare systems prioritize diagnostic stewardship and laboratory efficiency, blood culture testing is experiencing both operational refinement and strategic reassessment across hospital systems, independent laboratories, and outpatient facilities.

This executive summary synthesizes current dynamics affecting clinical practice, technology adoption, and organizational investment decisions. It highlights how shifts in diagnostic paradigms, policy environments, and end-user requirements are reshaping procurement preferences and implementation strategies, with implications for clinical laboratories, device manufacturers, and healthcare administrators seeking to optimize diagnostic value across care continuums.

How innovation, automation, supply chain resilience, and diagnostic stewardship are jointly reshaping laboratory workflows and clinical pathways in blood culture testing

The diagnostic landscape for bloodstream infection detection is undergoing transformative shifts driven by technological innovation, workflow optimization, and a reimagining of laboratory roles within care pathways. Conventional culture techniques continue to provide essential phenotypic information, yet molecular platforms and rapid identification methods have expanded the clinician's toolkit, enabling earlier de-escalation of empiric therapy and enhanced antimicrobial stewardship. This technological diversification has prompted laboratories to re-evaluate test algorithms and to adopt hybrid approaches that leverage both culture and molecular modalities for complementary strengths.

Operationally, increased adoption of automation across pre-analytical and analytical stages is altering laboratory staffing models and throughput expectations. Automation reduces manual variability and supports higher sample volumes, but it also necessitates investments in training, validation, and informatics to ensure seamless integration. At the same time, supply chain resilience has emerged as a strategic priority. Laboratories and suppliers are exploring redundancy in sourcing consumables and diversifying logistics to mitigate disruptions, which in turn affects procurement cycles and inventory management practices.

Clinically, there is an intensified focus on diagnostic stewardship, driven by payer scrutiny and institutional quality initiatives. Diagnostic pathways are being redesigned to emphasize timely and accurate detection while avoiding unnecessary testing. This shift influences adoption patterns for both automated and manual testing modalities and underscores the importance of actionable reporting, result turnaround time, and linkage to clinical decision support systems. Taken together, these trends are not only reshaping laboratory operations but also creating new opportunities for vendors and health systems to collaborate on integrated solutions that deliver measurable clinical and economic value.

Assessment of tariff-driven procurement stressors and supply chain strategies that are influencing cost structures, sourcing decisions, and distribution models across blood culture diagnostics

Recent tariff developments and trade policy adjustments have created material downstream effects for clinical laboratories, manufacturers, and distributors involved in blood culture diagnostics. Increased import duties on certain laboratory equipment and consumables can raise landed costs, prompting procurement teams to reassess supplier portfolios and negotiate longer-term contracts to stabilize pricing. In response, manufacturers may explore regionalization of production, alternative sourcing strategies, or changes to product configurations to mitigate tariff exposure while preserving margin structures.

These dynamics influence procurement behavior across end users, with hospitals and independent laboratories weighing the trade-offs between unit cost, reliability of supply, and vendor support commitments. Some organizations may prioritize stocking larger inventories of critical consumables to buffer against price volatility, while others will seek service models that reduce capital expenditure and transfer supply risk to vendors through managed services or reagent-rental agreements. Moreover, increased costs can accelerate interest in automation and workflow efficiency initiatives as organizations seek to offset higher per-unit prices through labor savings and reduced waste.

At the same time, regulatory and customs complexities associated with tariff implementation can extend lead times and complicate product launch strategies for new analyzers and consumables. Manufacturers and distributors are therefore adapting distribution and logistics frameworks, enhancing visibility across supply chains, and collaborating with customers to develop contingency plans. Collectively, these changes encourage more strategic procurement planning, foster supplier diversification, and create incentives for supply chain transparency and regional manufacturing investment to reduce the cumulative impact of tariff-related cost pressures.

Integrated segmentation analysis outlining product, end-user, technological, test-type, application, sample type, and mode implications that shape adoption and procurement dynamics

A granular view across product categories reveals distinct considerations for consumables and instruments that shape adoption and purchasing behavior. Consumables, encompassing bottles, culture media, and reagent kits, drive recurring operating cost and are evaluated for lot-to-lot consistency, storage requirements, and compatibility with automated systems. Instruments, including analyzers and automation systems, require capital planning, integration with laboratory information systems, and long-term service agreements. Consequently, buying decisions often balance the predictability of consumable supply against the efficiency gains and validation burden associated with analyzer deployment.

End-user segmentation highlights that ambulatory care centers, blood banks, diagnostic laboratories, and hospitals and clinics each follow different operational models and procurement imperatives. Ambulatory care delivery is typically split between independent clinics and physician offices, which prioritize ease of use and compact footprint. Blood banks emphasize reliability and regulatory compliance, whereas diagnostic laboratories - including hospital-based labs and independent labs - focus on throughput, turnaround time, and interoperability. Secondary and tertiary hospitals within the hospital and clinic segment demand scalable solutions, with tertiary centers often integrating advanced identification technologies.

Technology choices between conventional and molecular methods determine diagnostic pathways. Conventional culture remains essential for susceptibility testing and phenotypic confirmation, while molecular approaches, such as next generation sequencing and polymerase chain reaction, are increasingly used for rapid identification and characterization in complex cases. Test type preferences between automated and manual workflows reflect institutional priorities: automated platforms favor consistency and reduced hands-on time, whereas manual testing may persist in low-volume or resource-constrained settings. Application-specific requirements further differentiate use cases, with bacterial testing divided into gram-negative and gram-positive targets, fungal testing addressing filamentous fungi and yeast, and mycobacterial assays requiring specialized processing. Sample type considerations between plasma and whole blood influence processing protocols and instrument compatibility, and mode of delivery, whether central laboratory or point of care, including bedside and portable options, drives decisions about decentralization versus consolidated testing capacity. Together, these segmentation lenses provide a multidimensional framework for aligning product development, commercialization, and clinical implementation strategies.

Regional dynamics and infrastructure factors that steer technology adoption, procurement preferences, and service models across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Geographic dynamics create differentiated demand drivers and operational constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, each reflecting unique healthcare infrastructure, reimbursement models, and regional supply chain architectures. In the Americas, large integrated healthcare systems and a focus on diagnostic stewardship influence preferences for high-throughput automation and connectivity, while independent laboratories drive decentralized service provision. Within Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied purchasing frameworks and infrastructure heterogeneity, creating opportunities for modular solutions that accommodate diverse clinical settings. The Asia-Pacific region presents a mix of rapidly developing laboratory networks alongside mature centers of excellence, with considerable interest in scalable automation and molecular adjuncts to address both endemic and hospital-acquired infection challenges.

Regional procurement strategies differ in how they balance capital investment with operational expenditures. In well-capitalized systems, there is often appetite for advanced analyzers and integrated automation to support high-volume workflows, whereas in regions with resource constraints, manual or semi-automated approaches and durable consumables retain relevance. Cross-border logistics and tariff regimes further shape distribution strategies, prompting vendors and health systems to consider regional warehousing, local partnerships, and flexible service models to maintain supply reliability. Importantly, clinical priorities such as antimicrobial resistance surveillance, sepsis management programs, and public health reporting influence uptake of specific technologies and assays, leading to regionally tailored product roadmaps and support services that align with local clinical imperatives.

Competitive differentiation emerges from integrated solution portfolios, robust service networks, and targeted innovations that align with laboratory workflows and clinical priorities

Competitive positioning in the blood culture testing ecosystem is shaped by companies that excel in product reliability, integration capabilities, and service excellence. Leaders with broad portfolios across consumables and instrumentation gain advantage by offering end-to-end solutions that reduce the complexity of supplier management and validate seamless workflows. Organizations that invest in interoperability, data integration, and user-centered design to minimize hands-on time and streamline result reporting strengthen their value proposition to high-volume laboratories and hospital systems. Conversely, specialized companies that focus on niche technology areas-such as rapid molecular identification or high-sensitivity detection-can secure strategic placements within reference centers and tertiary institutions where advanced diagnostics are prioritized.

Partnership strategies and channel models also differentiate competitive approaches. Firms that cultivate robust distributor networks and local technical support are better positioned to serve diverse geographies, while those that offer embedded service programs, reagent-rental options, or outcome-linked contracting can alleviate capital constraints for customers. Additionally, companies that demonstrate supply chain transparency and responsiveness during periods of disruption build trust and long-term relationships with institutional buyers. Innovation pipelines that integrate automation, molecular adjuncts, and digital reporting capabilities offer incremental clinical and operational benefits, and organizations that align R&D investments with real-world laboratory workflows will likely secure preferential consideration in procurement decisions.

Ultimately, company success is increasingly tied to the ability to deliver demonstrable operational efficiencies, regulatory-compliant performance, and scalable support models that align with the clinical and financial objectives of diverse laboratory customers.

Actionable strategic priorities for vendors and laboratory leaders to enhance diagnostic value, operational resilience, and partner-focused commercialization models

Industry leaders seeking to strengthen market position and clinical impact should align investments with the twin objectives of improving diagnostic value and enhancing operational resilience. First, prioritize solutions that bridge phenotypic culture and rapid molecular identification to deliver clinically actionable results within the constraints of existing laboratory workflows. By doing so, organizations can support clinicians with timely information while preserving the downstream need for phenotypic susceptibility testing. Second, invest in automation and informatics that reduce manual variability and shorten turnaround times, ensuring that technology deployments are accompanied by robust training and validation programs to secure adoption.

Third, build supply chain flexibility through diversified sourcing, regional warehousing, and transparent inventory management. Such measures reduce vulnerability to tariff-induced cost shifts and logistical bottlenecks. Fourth, engage end users through outcome-focused service offerings, including reagent-rental models, managed reagent programs, and performance-based contracting that align vendor incentives with laboratory throughput and quality objectives. Fifth, pursue partnerships with clinical teams to embed diagnostic stewardship principles into testing algorithms and reporting formats, thereby strengthening the linkage between laboratory outputs and therapeutic decision-making. Finally, incorporate scalability into product design so that solutions are adaptable across ambulatory centers, blood banks, reference labs, and hospital systems, supporting phased upgrades and modular deployments that match capital cycles and clinical demand.

A rigorous mixed-methods research approach combining practitioner interviews, technical literature, and validation steps to produce actionable and reproducible diagnostic insights

This research employed a mixed-methods approach to synthesize clinical, commercial, and operational insights relevant to blood culture diagnostics. Primary inputs included structured interviews with laboratory directors, procurement officers, and clinical microbiologists, providing contextual understanding of workflow constraints, validation practices, and clinical use cases. Secondary sources comprised peer-reviewed literature, regulatory guidance, and manufacturer technical documentation to ensure alignment with current standards and performance expectations. The analysis integrated qualitative thematic synthesis with cross-sectional comparisons across product categories, end users, technologies, and geographic regions to identify consistent patterns and differentiated drivers.

To enhance reliability, findings were triangulated through multiple data streams and validated against practitioner feedback during expert review sessions. Methodological safeguards included explicit documentation of inclusion criteria for literature and technical documents, and careful delineation of technology definitions to distinguish conventional culture processes from molecular adjuncts. The approach prioritized reproducibility by outlining data sources, interview protocols, and analytic frameworks, enabling stakeholders to interrogate assumptions and adapt insights to their specific operational contexts. While this synthesis emphasizes practical implications, it remains grounded in established laboratory practice and contemporary diagnostic trends, providing a credible foundation for strategic planning and operational optimization.

Synthesis of clinical, operational, and strategic imperatives that converge to guide effective adoption and sustainable deployment of blood culture diagnostic solutions

Blood culture diagnostics are at an inflection point where technological innovation, supply chain considerations, and clinical priorities converge to reshape laboratory practice. Conventional culture systems remain central for phenotype-based susceptibility testing, while molecular and automated adjuncts are redefining expectations for speed and diagnostic resolution. These complementary modalities create opportunities for hybrid diagnostic pathways that balance rapid identification with comprehensive susceptibility determination, thereby improving stewardship and patient outcomes. Operationally, laboratories must navigate tariff-related cost pressures, supply chain variability, and the demands of integration and validation when adopting new platforms.

Strategic responses that emphasize interoperability, regional supply resilience, and outcome-focused service models will be most effective in sustaining performance and value. By aligning product portfolios with the nuanced needs of different end users - from bedside point-of-care contexts to high-throughput reference laboratories - vendors and healthcare organizations can enhance diagnostic impact while managing total cost of operation. Looking ahead, collaborative approaches that connect manufacturers, laboratory leaders, and clinical teams will accelerate the translation of technological advances into measurable clinical benefits, supporting safer, faster, and more targeted care for patients with suspected bloodstream infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI driven pathogen identification software into automated blood culture platforms enabling faster diagnosis
  • 5.2. Expansion of rapid molecular blood culture assays to detect antimicrobial resistance markers at point of care
  • 5.3. Adoption of continuous monitoring blood culture systems reducing time to detection in critical care settings
  • 5.4. Growth of multiplex PCR panels paired with traditional culture for comprehensive sepsis pathogen screening
  • 5.5. Increasing collaboration between diagnostic companies and hospitals to implement antibiotic stewardship programs
  • 5.6. Emerging regulatory frameworks like IVDR influencing design and validation of blood culture diagnostics in Europe
  • 5.7. Rising demand for portable point of care blood culture devices in remote and resource limited healthcare facilities
  • 5.8. Impact of COVID 19 pandemic on blood culture utilization and sepsis management protocols in hospitals
  • 5.9. Focus on sustainability and reduced plastic waste in single use blood culture bottles and ancillary consumables
  • 5.10. Strategic mergers and acquisitions driving consolidation among leading blood culture system manufacturers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Culture Test Market, by Product

  • 8.1. Consumables
    • 8.1.1. Bottles
    • 8.1.2. Culture Media
    • 8.1.3. Reagent Kits
  • 8.2. Instruments
    • 8.2.1. Analyzers
    • 8.2.2. Automation Systems

9. Blood Culture Test Market, by End User

  • 9.1. Ambulatory Care Centers
    • 9.1.1. Independent Clinics
    • 9.1.2. Physician Offices
  • 9.2. Blood Banks
  • 9.3. Diagnostic Laboratories
    • 9.3.1. Hospital Based Labs
    • 9.3.2. Independent Labs
  • 9.4. Hospitals & Clinics
    • 9.4.1. Secondary Hospitals
    • 9.4.2. Tertiary Hospitals

10. Blood Culture Test Market, by Technology

  • 10.1. Conventional
  • 10.2. Molecular
    • 10.2.1. Next Generation Sequencing
    • 10.2.2. Polymerase Chain Reaction

11. Blood Culture Test Market, by Test Type

  • 11.1. Automated
  • 11.2. Manual

12. Blood Culture Test Market, by Application

  • 12.1. Bacterial
    • 12.1.1. Gram Negative
    • 12.1.2. Gram Positive
  • 12.2. Fungal
    • 12.2.1. Filamentous Fungi
    • 12.2.2. Yeast
  • 12.3. Mycobacterial

13. Blood Culture Test Market, by Sample Type

  • 13.1. Plasma
  • 13.2. Whole Blood

14. Blood Culture Test Market, by Mode

  • 14.1. Central Lab
  • 14.2. Point Of Care
    • 14.2.1. Bedside
    • 14.2.2. Portable

15. Blood Culture Test Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Blood Culture Test Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Blood Culture Test Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Becton Dickinson and Company
    • 18.3.2. bioMerieux SA
    • 18.3.3. Thermo Fisher Scientific Inc.
    • 18.3.4. Siemens Healthineers AG
    • 18.3.5. Sysmex Corporation
    • 18.3.6. Accelerate Diagnostics, Inc.
    • 18.3.7. bio-Rad Laboratories, Inc.
    • 18.3.8. Sigma-Aldrich
    • 18.3.9. Thermo Fisher Scientific Inc.
    • 18.3.10. F. Hoffmann-La Roche

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BLOOD CULTURE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BLOOD CULTURE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD CULTURE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CULTURE TEST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BOTTLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CULTURE MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REAGENT KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PHYSICIAN OFFICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY FILAMENTOUS FUNGI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MYCOBACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY CENTRAL LAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY BEDSIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY PORTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BLOOD CULTURE TEST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MOLECULAR, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY BACTERIAL, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY FUNGAL, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY MODE, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA BLOOD CULTURE TEST MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BLOOD CULTURE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD